Background-The tumor necrosis factor receptor superfamily, which includes CD40, LIGHT, and OX40, plays important roles in atherosclerosis. CD137 (4-1BB), a member of the tumor necrosis factor receptor superfamily, has been reported to be expressed in human atherosclerotic lesions. However, limited information is available on the precise role of CD137 in atherosclerosis and the effects of blocking CD137/CD137 ligand signaling on lesion formation. Methods and Results-We generated CD137-deficient apolipoprotein E-knockout mice (ApoE Ϫ/Ϫ CD137 Ϫ/Ϫ ) and LDL-receptor-knockout mice (Ldlr Ϫ/Ϫ CD137 Ϫ/Ϫ ) to investigate the role of CD137 in atherogenesis. The deficiency of CD137 induced a reduction in atherosclerotic plaque lesions in both atherosclerosis mouse models, which was attributed to the downregulation of cytokines such as interferon-␥, monocyte chemoattractant protein-1, and tumor necrosis factor-␣. CD137 signaling promoted the production of inflammatory molecules, including monocyte chemoattractant protein-1, interleukin-6, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1, in endothelial cells. Stimulation of CD137 ligand signaling activated monocytes/macrophages and augmented the production of proinflammatory cytokines in atherosclerotic vessels. Conclusions-CD137/CD137 ligand signaling plays multiple roles in the progression of atherosclerosis, and thus, blockade of this pathway is a promising therapeutic target for the disease. (Circulation. 2010;121:1124-1133.) 
A therosclerosis is an inflammatory disease of the arterial wall that involves both innate and adaptive T-celldriven immunoinflammatory responses. [1] [2] [3] Accumulating evidence on human disease suggests that autoantigens are involved in the promotion of atherosclerosis. In T cells isolated from fresh human plaques, oxidized LDL (oxLDL) is a major autoantigen that triggers an immune response that involves activation of T cells and subsequent stimulation of local cytokine release by monocytes/macrophages, such as monocyte chemoattractant protein-1 (MCP-1). 4 -7 T-cell activation is further enhanced by ligand binding to the costimulatory receptors CD40, CD137, and OX40, which are expressed on the cell surface. Enhanced T-cell activation by ligand binding to costimulatory receptors significantly augments cytokine release by monocytes/macrophages, further exacerbating inflammation and promoting atherosclerosis. 8 -11 Here, we demonstrate that CD137 contributes to T-cell activation and generation of interferon (IFN)-␥ in atherosclerotic mice. IFN-␥, in turn, induces monocytes/macrophages to augment proinflammatory cytokine production through a positive feedback mechanism, thereby facilitating atherogenic plaque formation.
Clinical Perspective on p 1133
Several recent reports suggest that CD137 and its ligand, CD137L, are important contributory factors to colitis, osteoclastogenesis, and toll-like receptor signaling in macrophages. [12] [13] [14] CD137L is a type II membrane glycoprotein of the tumor necrosis factor (TNF) receptor superfamily expressed on monocytes, macrophages, dendritic cells, and activated B cells. In general, TNF receptor superfamily members are initiators of inflammatory disease. The receptor for CD137L is CD137, a 30-kDa glycoprotein of the TNF receptor superfamily and a well-known T-cell costimulatory molecule. CD137 is expressed on activated CD4 ϩ T cells, CD8 ϩ T cells, natural killer cells, resting monocytes, and dendritic cells. [15] [16] [17] [18] [19] To define the role of CD137 in the immune system and immune-related diseases, the CD137deficient mouse appears to be useful. CD137-deficient mice have been demonstrated to show enhanced T-cell response but normal T-cell development. 20, 21 Vinay and colleagues 22 also showed that CD137-deficient mice have a reduced number of natural killer cells and natural killer T cells, which leads to resistance to lipopolysaccharide-induced shock syndrome. Recently, although CD137 deficiency increases the number of myeloid progenitor cells and mature dendritic cells, the longevity of dendritic cells was decreased in CD137-deficient mice, which led to impaired dendritic cell function. 23, 24 Therefore, CD137 appears to have various roles in the immune system.
Olofsson and colleagues 25 clearly showed CD137 expression in human atherosclerotic plaques. They also showed that treatment with an agonistic CD137 antibody promotes development of plaque inflammation in a mouse atherosclerosis model. 25 However, although agonistic CD137 antibody has been used to understand the function of CD137 in several previous studies, Niu and colleagues 26 showed that mice treated with anti-CD137 antibody have several immune abnormalities, which indicates that an agonistic antibody may not properly reveal the function of CD137 in atherosclerosis. Thus, another animal model system is needed to understand the role and underlying mechanism of CD137 in atherosclerosis.
In the present study, we examined the contribution of CD137 to atherosclerosis in 2 well-established mouse models of atherosclerosis using LDL-receptor-deficient (Ldlr Ϫ/Ϫ ) or apolipoprotein E-deficient (ApoE Ϫ/Ϫ ) mice 27, 28 (C57BL/6J congenic background; online-only Data Supplement Figure I ). Our findings show that CD137 is a significant atherosclerosis-promoting factor mainly expressed on leukocytes and endothelial cells at atherosclerotic lesion sites. Moreover, we show that loss of CD137 strongly attenuates atherosclerosis in Ldlr Ϫ/Ϫ and ApoE Ϫ/Ϫ mice, which implicates CD137 as a potential therapeutic target for atherosclerosis disease control.
Methods

Experimental Animals
CD137-deficient mice, generated by embryonic stem cell homologous recombination, 20 have no abnormality in the weight of spleen and thymus or other hematologic parameters (online-only Data Supplement Table I) . We cross-bred these mice with ApoE or Ldlr knockout mice to generate ApoE/CD137 or Ldlr/CD137 doubledeficient (ApoE Ϫ/Ϫ CD137 Ϫ/Ϫ or Ldlr Ϫ/Ϫ CD137 Ϫ/Ϫ ) mice. All strains are C57BL/6 congenic lines backcrossed more than 10 times with C57BL/6j. Animal study protocols were approved by the Animal Care Committee of Ewha Womans University.
Statistical Analysis
Results were analyzed with Wilcoxon rank sum test if 2 groups were compared or Kruskal-Wallis test followed by Wilcoxon rank sum test for multiple comparisons if more groups were compared with a control group. For the matched experiment, the results were analyzed with Wilcoxon signed rank test.
Supplemental Methodology
For detailed methods related to cell culture and cytokine treatment, aortic organ culture, analysis of atherosclerosis, immunostaining, T-cell response to oxLDL, real-time reverse-transcription polymerase chain reaction, monocyte migration assay, monocyte adhesion assay, and bone marrow transplantation, see the online-only Data Supplement.
Results
Expression of CD137 and CD137L in T Cells and Macrophages in Mouse Atherosclerotic Lesions
Atherogenic plaques contain a marked increase in numbers of macrophages and T cells, as evident from the expression of CD68 and CD3 markers, respectively, in the affected sites. Also, because CD137 and CD137L have been reported to be expressed in human atherosclerotic lesions, 25 we initially examined whether CD137 and CD137L are expressed in mouse atherosclerotic lesion sites. Immunohistochemical analysis of atheromas from the aortic sinuses of Ldlrdeficient (Ldlr Ϫ/Ϫ ) mice fed a high-fat diet revealed that CD3 ϩ T cells and CD68 ϩ macrophages indeed expressed CD137 and CD137L, respectively (Figures 1a through 1f ). Atherosclerotic lesions from Ldlr Ϫ/Ϫ CD137 Ϫ/Ϫ mice were not stained by anti-CD137 antibody (Figure 1c ), as expected, but stained with anti-CD137L antibody (Figure 1f ).
Deficiency of CD137 Reduces Atherosclerosis in Mice on Both Chow and High-Fat Diets
Multiple studies have demonstrated that T cells influence atherosclerotic plaque formation and progression of atherogenesis. 29 -31 For instance, atherosclerosis-prone ApoE Ϫ/Ϫ mice display slower progression of atherosclerosis if the Rag gene, which is required for lymphocyte development, is also lost (ApoE Ϫ/Ϫ Rag Ϫ/Ϫ ) when fed a normal chow diet. Those results indicate loss of Rag, which results in lymphocyte deficiency, reduces atherosclerosis formation. However, a change to a high-fat diet eliminated this reducing effect. Because CD137 is expressed in T cells at atherosclerotic lesion sites (Figure 1 ), we hypothesized that loss of CD137 may lead to reduced atherosclerotic plaque formation in mice by attenuating the activation of T cells. Initially, we compared the atherosclerotic lesion area in ApoE and CD137 double-deficient mice (ApoE Ϫ/Ϫ CD137 Ϫ/Ϫ ) versus control mice (ApoE Ϫ/Ϫ CD137 ϩ/ϩ ) fed a normal chow diet. Compared with ApoE Ϫ/Ϫ CD137 ϩ/ϩ mice, the atherogenic areas in the aortic arch and descending aorta were decreased significantly in normal chow diet-fed male and female ApoE Ϫ/Ϫ CD137 Ϫ/Ϫ mice at 66 weeks of age, which is age-matched to approximately 55 human years (Figure 2a ). Plaque area in the aortic sinus was also reduced in ApoE Ϫ/Ϫ CD137 Ϫ/Ϫ mice compared with ApoE Ϫ/Ϫ CD137 ϩ/ϩ mice of both sexes (Figure 2b) . Accordingly, we measured lesion formation in mice fed a high-fat diet. In such mice, the atherogenic region in the aortic arch and descending aorta was reduced significantly, even in the Ldlr Ϫ/Ϫ CD137 Ϫ/Ϫ group (Figure 2c ). Plaque lesions in the aortic sinus were additionally reduced in Ldlr Ϫ/Ϫ CD137 Ϫ/Ϫ mice (Figure 2d ). Moreover, the effect of CD137 loss was also observed in ApoE Ϫ/Ϫ CD137 Ϫ/Ϫ mice fed a high-fat diet (online-only Data Supplement Figure II ). However, there were no significant differences in blood lipid profiles between experimental groups (online-only Data Supplement Table II ). Furthermore, CD137 deficiency did not affect body weight (online-only Data Supplement Table III ) or blood 
levels of glucose (Ldlr
0Ϯ4.2 versus 93.8Ϯ13.8 mg/dl) and insulin (CD137 ϩ/ϩ B6 versus CD137 Ϫ/Ϫ B6, 0.56Ϯ0.11 versus 0.53Ϯ0.09 ng/mL). These data collectively suggest that CD137 function may extend beyond T cells for atherosclerotic plaque formation.
CD137 Deficiency Leads to Reduced IFN-␥ Production in Atherosclerotic Mice
Costimulatory receptors on T cells mediate T-cell activation and induce cytokine secretion in immune responses. Th1
T-cell subtypes release cytokines, such as IFN-␥ and TNF-␣, after activation. 32 These cytokines activate macrophages and vascular cells, facilitate inflammation, and participate in cellular immunity. We examined whether T cells that express CD137 also produce cytokines such as IFN-␥ in atherosclerotic plaques. Immunohistochemical analysis of atheromas in mice revealed CD4 ϩ /IFN-␥ ϩ /CD137 ϩ and CD8 ϩ /IFN-␥ ϩ / CD137 ϩ T cells were present in lesion sites (Figures 3a and  3b ). These findings were also observed in human aortic lesions (online-only Data Supplement Figures III and IV). Next, we compared IFN-␥ expression in plaque lesions of ApoE Ϫ/Ϫ CD137 ϩ/ϩ and ApoE Ϫ/Ϫ CD137 Ϫ/Ϫ mice. CD137 deficiency resulted in a significant decrease in IFN-␥ staining within plaques ( Figure 3c ). Moreover, IFN-␥ messenger RNA expression was decreased in the aortas of CD137deficient mice (Figure 3d ). Accordingly, to determine whether CD137 contributes to IFN-␥ production by T cells, we examined IFN-␥ levels in activated T cells by oxLDL treatment in CD137-deficient hyperlipidemic mice. IFN-␥ production by splenic CD4 ϩ and CD8 ϩ T cells induced by oxLDL was decreased significantly in Ldlr Ϫ/Ϫ CD137 Ϫ/Ϫ and ApoE Ϫ/Ϫ CD137 Ϫ/Ϫ mice (Figure 3e ), which indicates that CD137 helps contribute to a T-cell-activated inflammatory response in atherogenesis.
CD137 Signaling Enhances the Production of Proinflammatory Molecules in Endothelial Cells
Recent studies show that CD137 expression induced in endothelial cells during inflammation and tumorigenesis mediates the migration of monocytes/macrophages. 33, 34 In the present study, we observed CD137 expression on endothelial cells in inflammation sites of atherosclerotic lesions in mice (Figures 4a through 4g) , whereas normal endothelium did not stain for CD137 ( Figure 4h ). Next, we investigated the significance of CD137 expression on monocyte/macrophage migration under inflammatory conditions. First, primary endothelial cells treated with TNF-␣ simulated inflammatory conditions, and we noted CD137 expression was increased significantly (Figure 4i ). We also found that CD137 expression was increased by lipopolysaccharide treatment (onlineonly Data Supplement Figure V) , which suggests that various inflammatory stimuli may induce CD137 expression in the endothelial cell. We next determined the outcome of increased CD137 expression under simulated conditions of inflammation. Endothelial cells isolated from CD137 ϩ/ϩ and CD137 Ϫ/Ϫ mice were stimulated with TNF-␣ for 24 hours. The cells were cultured on CD137 agonistic antibody (3H3)precoated plates to activate CD137 receptor signaling. We noted that stimulation of CD137 signaling upregulated the expression of adhesion molecules (vascular cell adhesion molecule-1 and intercellular adhesion molecule-1) and chemoattractants, including MCP-1 and interleukin-6 ( Figures 5a through 5d ), which are known to be important for cell migration. These changes were absent in CD137 Ϫ/Ϫ endothelial cells. In addition, conditioned culture medium from CD137 ϩ/ϩ endothelial cells stimulated with CD137 agonistic antibody was more effective at inducing macrophage migration than that from CD137 Ϫ/Ϫ or CD137 ϩ/ϩ endothelial cells not treated with an agonistic antibody (Figure 5e ). These results indicate that endothelial CD137 activation induces infiltration of macrophages into lesion sites by inducing the secretion of cytokines, including MCP-1 and interleukin-6, as well as upregulation of cell adhesion molecules. Furthermore, we performed a monocyte adhesion assay in cultures of endothelial cells and aortic tissues from CD137 ϩ/ϩ and CD137 Ϫ/Ϫ mice and found that monocyte attachment was decreased significantly in CD137 Ϫ/Ϫ endothelial cells and intact aortic endothelium compared with the attachment in CD137 ϩ/ϩ counterparts (Figures 5f and 5g ). In view of the above results, we investigated the extent of macrophage infiltration in the aortic sinus lesions of ApoE Ϫ/Ϫ CD137 ϩ/ϩ and ApoE Ϫ/Ϫ CD137 Ϫ/Ϫ mice. CD137 deficiency led to a significant reduction in monocyte/macrophage infiltration into the lesion area (online-only Data Supplement Figure  VI) . Thus, endothelial CD137 may mediate the recruitment of macrophages into lesion sites by affecting levels of cytokine productions or cell adhesion molecules in endothelial cells.
CD137L Signaling Activation by Soluble CD137 Protein Also Contributes to the Production of MCP-1 and TNF-␣ in Atherosclerotic Aorta
Previous studies demonstrate that TNF receptors induce reverse signaling through interactions with their ligands. 35 Accordingly, we hypothesized that reverse CD137L signaling activated by CD137 might increase the production of proinflammatory molecules in lesion sites. First, to evaluate TNF-␣ and MCP-1 expression levels in atherosclerotic lesions, we measured the respective immunopositive areas. The TNF-␣-and MCP-1-immunopositive area size was markedly reduced in atherosclerotic lesion sites of ApoE Ϫ/Ϫ CD137 Ϫ/Ϫ mice (Figures 6a and 6b ). Messenger RNA levels of both cytokines were also reduced in the aortas of ApoE Ϫ/Ϫ CD137 Ϫ/Ϫ mice (Figure 6c ). Next, to test the effect of CD137L activation on cytokine production, we treated organ cultures of atherosclerotic aorta from ApoE Ϫ/Ϫ CD137 Ϫ/Ϫ mice with CD137-Fc. 36 Expression of TNF-␣ and MCP-1 Figure 5 . Activation of CD137 signaling in endothelial cells increases the production of proinflammatory molecules. Quantitative reverse-transcription polymerase chain reaction for messenger RNA levels of (a) MCP-1, (b) interleukin-6 (IL-6), (c) vascular cell adhesion molecule-1 (VCAM-1), and (d) intercellular adhesion molecule-1 (ICAM-1). TNF-␣-treated or nontreated endothelial cells from B6 mice were incubated with agonistic CD137 or isotype antibody. e, Macrophage migration assay. CD137 Ϫ/Ϫ and CD137 ϩ/ϩ endothelial cells (1ϫ10 5 cells/mL) from 6-to 8-week-old mice were cultured on 12-well plates coated with CD137 agonistic antibody (5 g/mL) and stimulated with TNF-␣ (10 ng/mL) for 24 hours. The conditioned media from the endothelial cell culture were transferred to transwell plates, and peritoneal macrophages from B6 mice (10 weeks old, 1.4ϫ10 5 cells) were added to transwell inserts. After 12 hours of incubation at 37°C and 5% CO 2 , the cells that migrated from transwell inserts to the plate were counted. f, Monocyte adhesion assay. The attached green fluorescent protein-positive monocytes on the endothelial cells from CD137 Ϫ/Ϫ or CD137 ϩ/ϩ mice were counted under a fluorescent microscope. g, Monocyte adhesion assay in aortic organ culture. Green fluorescent protein-positive monocytes attached to endothelium of the aortas from 20-week-old ApoE Ϫ/Ϫ CD137 Ϫ/Ϫ or ApoE Ϫ/Ϫ CD137 ϩ/ϩ mice were counted under a fluorescent microscope. *P calculated by Kruskal-Wallis test. Ab indicates antibody.
was increased significantly after 12 hours of treatment with CD137-Fc compared with atherosclerotic aorta treated with control immunoglobulin G (IgG; Figure 6d) ; however, treatment of the aorta organ cultures from ApoE Ϫ/Ϫ CD137 ϩ/ϩ mice with CD137-Fc intriguingly did not have an increased effect on cytokine production (data not shown). This discrepancy in relation to CD137 ϩ/ϩ atherosclerotic aorta appears to be due to the redundancy of CD137 in aortic lesions. We next analyzed the effect of CD137-Fc treatment on CD68 ϩ macrophages, which mainly express CD137L (Figures 1e and 1f ) and can produce MCP-1 and TNF-␣ after treatment with CD137-Fc (online-only Data Supplement Figure VII) . We analyzed cell culture media for cytokine production in lipopolysaccharide-activated peritoneal macrophages and RAW264.7 macrophages. Although RAW264.7 macrophages have been reported to express CD137L without stimulation, mouse peritoneal macrophages need to be activated by lipopolysaccharide to induce CD137L expression on the cell surface. 37 Culturing RAW264.7 macrophages with CD137-Fc enhanced MCP-1 and TNF-␣ secretion in a dose-dependent manner (online-only Data Supplement Figure VIII) . In lipopolysaccharide-activated peritoneal macrophages, treatment with CD137-Fc increased MCP-1 and TNF-␣ secretion significantly, whereas cytokine production was not changed by CD137-Fc treatment in nonactivated peritoneal macrophages (Figures 6e and 6f) .
The present results suggest that CD137 may play a role in atherosclerosis via combined functions in immune cells and endothelium. Next, we investigated the relative contribution of CD137 Ϫ/Ϫ in immune and vascular cells to atherosclerotic lesion formation using bone marrow transplantation experiments. After 8 weeks of a high-fat diet, all bone marrowreconstituted mice developed early atherosclerotic lesions (online-only Data Supplement Figures IX and X) . When we analyzed the atherosclerotic lesions of each group, we found that the Ldlr Ϫ/Ϫ CD137 ϩ/ϩ or Ldlr Ϫ/Ϫ CD137 Ϫ/Ϫ mice replenished with CD137-deficient bone marrow had significantly fewer atherosclerotic lesions in aortic sinus than their counterparts. However, Ldlr Ϫ/Ϫ CD137 Ϫ/Ϫ mice replenished with wild-type bone marrow did not have fewer atherosclerotic Aortic segments from ApoE Ϫ/Ϫ mice (nϭ7, 37 weeks old) were collected and divided in half (longitudinally). One set was stimulated with 5 g of recombinant CD137-Fc chimera, and the other set was incubated with 5 g of human IgG as a control. After incubation at 37°C and 5% CO 2 for 13 hours, messenger RNA expression levels of TNF-␣ and MCP-1 were analyzed with real-time reverse-transcription polymerase chain reaction. Messenger RNA levels in CD137-Fc-treated aortas were normalized to the levels of human IgG-treated aorta. e and f, Levels of MCP-1 and TNF-␣ released from peritoneal macrophages stimulated by CD137-Fc. Lipopolysaccharide (LPS; 10 g/mL) was added to the culture to activate macrophages. *P calculated by Kruskal-Wallis test.
lesions than Ldlr Ϫ/Ϫ CD137 ϩ/ϩ mice replenished with wildtype bone marrow, which indicates that deprivation of vascular CD137 only is not sufficient to reduce atherosclerotic lesion formation. Thus, the present bone marrow transplantation experiment clearly shows that CD137 in immune cells has an important role in atherosclerotic lesion formation. Nevertheless, because leukocyte adhesion molecules and cytokine production levels were decreased significantly in CD137-deficient endothelium in the present in vitro and ex vivo experiments, we still speculate that endothelial CD137 may have a role in atherosclerotic lesion formation at more advanced stages. Further studies are needed to elucidate the exact role of endothelial CD137 at advanced stages of atherosclerosis. Collectively, the mechanism involves a positive-feedback loop that includes CD137 signaling between T cells and monocytes/macrophages, which act to promote cytokine production, further increasing inflammation and atherosclerosis (Figure 7 ).
Discussion
Here, using 2 different mouse atherosclerosis models, we have demonstrated that CD137/CD137L signaling contributes significantly to the formation of atherosclerotic lesions, and we present the cellular mechanisms underlying CD137-dependent atherosclerosis development. Initially, T cells with CD137 signaling displayed increased IFN-␥ production. T cells lacking CD137 function displayed little response to the pathways, which led to attenuation of atherosclerosis in hyperlipidemic Ldlr Ϫ/Ϫ and ApoE Ϫ/Ϫ mice. Second, CD137 in endothelial cells plays a role in monocyte attachment to endothelium. We showed that endothelial cells in atherosclerotic plaques expressed CD137, and CD137-deficient endothelial cells were less effective at inducing monocyte recruitment and attachment. Finally, CD137 bidirectionally stimulated CD137L signaling in the lesion and macrophages, which led to an increase in proatherogenic molecules. The results of the present study indicate that CD137 plays significant roles in atherosclerotic lesion formation through combined actions in T cells, macrophages, and endothelial cells.
Clearly, T cells are an important immune component in atherosclerosis, and atherosclerotic lesions can be reduced by attenuating their activity. The present results show that CD137 stimulates T-cell activity. We additionally confirmed that stimulation of CD137 signaling with an agonistic CD137 antibody activates both CD4 ϩ and CD8 ϩ T cells, which leads to IFN-␥ secretion (data not shown). However, the role of CD137 in T-cell activation is currently a controversial issue. In CD137 Ϫ/Ϫ mice, proliferation of splenocytes is markedly increased in response to mitogen or anti-CD3 antibody compared with wild-type mice. 20 Moreover, CD137 Ϫ/Ϫ mice display enhanced CD4 ϩ T-cell response to specific antigens, with no defects in T-cell development. 21 Moreover, treatment with the agonistic anti-CD137 antibody ameliorates the inflammatory response in several autoimmune mouse models. Sun and colleagues 38 demonstrated that treatment with an agonistic CD137 antibody initially increases the antigenspecific CD4 ϩ T-cell response, followed by a subsequent decrease in the T-cell response, which leads to amelioration of experimental autoimmune encephalomyelitis. Therefore, it appears that CD137 affects T-cell activation to different extents according to the duration of signaling. In the present study, we showed that CD137 deficiency decreases the CD4 ϩ and CD8 ϩ T-cell responses to oxLDL in ApoE Ϫ/Ϫ and Ldlr Ϫ/Ϫ mice with chronic vascular inflammation. The present results contradict previous studies 20, 21 that reported enhanced T-cell response to specific antigens in CD137 Ϫ/Ϫ mice. One possible explanation for this discrepancy is that the chronic inflammation required for atherosclerosis development causes an initially enhanced T-cell response but leads to T-cell death or anergy after chronic stimulation in CD137-deficient hyperlipidemic mice.
CD137 is expressed in vessel walls of tumors and inflammatory sites. Stimulation of CD137 signaling in Figure 7 . Proposed model for the roles of CD137/CD137L signaling in atherosclerosis. Ligation of CD137 and CD137L can induce activation of macrophages and lymphocytes through its bidirectional signaling. The activated lymphocytes produce more IFN-␥, which leads to another phase of recruitment and activation of macrophages. The activated macrophages produce more cytokines, including TNF-␣ and MCP-1, which causes endothelial CD137 expression. The endothelial CD137 signaling induces the production of MCP-1 and cell adhesion molecules, probably leading to enhancement of leukocyte recruitment to the lesion. Taken together, CD137/CD137L signaling facilitates atherosclerosis through its positivefeedback mechanism related to lymphocytes, macrophages, and endothelial cells. IL-6 indicates interleukin-6; VCAM-1, vascular cell adhesion molecule-1; and ICAM-1, intercellular adhesion molecule-1.
endothelial cells increases monocyte migratory activity. 33 Recent reports show that in human atherosclerosis, CD137 is expressed in endothelial cells. Activation of endothelial CD137 signaling with CD137L enhances the expression of cell adhesion molecules required for migration, including vascular cell adhesion molecule-1 and intercellular adhesion molecule-1. 25 We confirmed that CD137 was expressed in the endothelial cells of mouse atherosclerotic lesions, and this expression was inducible by TNF-␣ stimulation. Furthermore, stimulation of CD137 signaling increased the levels of both cell adhesion molecules (vascular cell adhesion molecule-1 and intercellular adhesion molecule-1) and MCP-1 and interleukin-6 in TNF-␣treated endothelial cells. The inflammatory cytokines secreted after CD137 stimulation promote macrophage migration. Therefore, although the contribution of endothelial CD137 to atherosclerotic lesion formation in the present bone marrow transplantation experiment was minor, CD137 in endothelial cells may play a role in more advanced atherosclerosis development.
Bidirectional signaling through a receptor and cell surface-bound ligand has been identified for TNF and TNF receptor family members. 39, 40 Reverse signaling through the ligands offers the advantage of rapid feedback and fine-tuning of biological responses. However, limited information is currently available on the signaling mechanism of CD137L induced by CD137. Kang and colleagues 14 reported that CD137L is essential for the sustained production of TNF-␣ in toll-like receptor-mediated macrophage activation. However, sustained production of TNF-␣ by CD137L is independent of CD137. In the present study, to elucidate the roles of CD137L activation by its receptor, CD137, lipopolysaccharide-activated peritoneal macrophages were treated with CD137 fusion protein. CD137-Fc treatment enhanced the production of proinflammatory cytokines such as TNF-␣ and MCP-1 in the activated peritoneal macrophages. Conversely, the increases in area and messenger RNA expression levels for these molecules in the atherosclerotic region are decreased significantly in CD137 Ϫ/Ϫ mice. Furthermore, we demonstrated that CD137 protein in atherosclerotic aortas in ex vivo culture increases the messenger RNA expression of inflammatory molecules in lesion sites. These results strongly support the idea that reverse CD137L signaling contributes to atherosclerosis.
We suggest that CD137 not only regulates T-cell activation as a costimulatory receptor but also mediates atherosclerosis via effects on endothelial cells and macrophages (Figure 7) . Moreover, because CD137L is expressed in other cell types, including dendritic cells and activated B cells, CD137/ CD137L signaling may contribute to atherosclerosis in these cells. Furthermore, in our preliminary study, we found that macrophages can also express CD137 by oxLDL treatment (online-only Data Supplement Figures XI and XII) , which implies that CD137 in macrophages may affect the atherosclerotic event. However, these theories require further investigation. In conclusion, the results of the present study indicate that CD137 deficiency can reduce atherosclerosis, and blocking of CD137/CD137L signaling offers a valuable therapeutic target in atherosclerosis.
